公开(公告)号：US20140213597A1

公开(公告)日：2014-07-31

申请号：US14227281

申请日：2014-03-27

申请人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

发明人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

IPC分类号： G01N33/20

CPC分类号： G01N33/20 ,  A61K31/4439 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/56 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/811

摘要： The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

摘要翻译： 本发明提供了治疗急性冠状动脉综合征的方法，并且基于人类受试者的生物流体中催化铁的升高来预测不良心脏事件。 本发明的一个实施方案提供了在呈现胸痛时在人类受试者中早期检测急性冠状动脉综合征（ACS）的方法。 该方法包括分析生物流体的测试样品中的催化铁量并检测人类受试者的急性冠脉综合征。

公开(公告)号：US20060223862A1

公开(公告)日：2006-10-05

申请号：US11412237

申请日：2006-04-26

申请人： Sudhir Shah

发明人： Sudhir Shah

IPC分类号： A61K31/195 ,  A61K31/444

CPC分类号： G01N33/6893 ,  A61K31/16 ,  A61K31/164 ,  A61K31/195 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4422 ,  A61K31/444 ,  G01N33/84 ,  G01N2800/347

摘要： Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.

公开(公告)号：US08192997B2

公开(公告)日：2012-06-05

申请号：US12882809

申请日：2010-09-15

申请人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

发明人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

IPC分类号： G01N33/20

CPC分类号： G01N33/20 ,  A61K31/4439 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/56 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/811

摘要： The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

摘要翻译： 本发明提供了治疗急性冠状动脉综合征的方法，并且基于人类受试者的生物流体中催化铁的升高来预测不良心脏事件。 本发明的一个实施方案提供了在呈现胸痛时在人类受试者中早期检测急性冠状动脉综合征（ACS）的方法。 该方法包括分析生物流体的测试样品中的催化铁量并检测人类受试者的急性冠脉综合征。

公开(公告)号：US07927880B2

公开(公告)日：2011-04-19

申请号：US12124185

申请日：2008-05-21

申请人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

发明人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

IPC分类号： G01N33/20

CPC分类号： G01N33/20 ,  A61K31/4439 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/56 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/811

摘要： The invention provides methods for early diagnosis or detection of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

摘要翻译： 本发明提供了用于早期诊断或检测急性冠状动脉综合征的方法，并且基于人类受试者的生物流体中催化铁的升高来预测不良心脏事件。 本发明的一个实施方案提供了在呈现胸痛时在人类受试者中早期检测急性冠状动脉综合征（ACS）的方法。 该方法包括分析生物流体的测试样品中的催化铁量并检测人类受试者的急性冠脉综合征。

公开(公告)号：US20060183245A1

公开(公告)日：2006-08-17

申请号：US11350660

申请日：2006-02-09

申请人： Sudhir Shah ,  Alexei Basnakian ,  Yousri Barri

发明人： Sudhir Shah ,  Alexei Basnakian ,  Yousri Barri

IPC分类号： G01N33/543 ,  C07K16/18

CPC分类号： A61M1/3679 ,  A61M1/3486 ,  A61M2202/046 ,  C07K16/18 ,  C07K16/28 ,  G01N33/6854 ,  G01N33/92 ,  G01N2800/044 ,  G01N2800/323 ,  Y10S435/967 ,  Y10S436/811 ,  Y10T436/105831 ,  Y10T436/106664 ,  Y10T436/12 ,  Y10T436/25125 ,  Y10T436/25375 ,  Y10T436/255

摘要： The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.

摘要翻译： 本发明提供一种确定个体是否处于动脉粥样硬化风险的方法，包括测量从该个体获得的样品中cLDL水平和/或cLDL自身抗体的步骤。 本发明还公开了一种用单体氨基酸或其他氨基甲酰化酶或非酶抑制剂还原个体中氨基甲酰化的方法。 本发明还提供了通过从个体的血液或血浆直接消除cLDL来降低cLDL水平的方法。 本发明还提供了通过抑制个体中cLDL的聚集和/或沉积来治疗或预防个体动脉粥样硬化的方法。

公开(公告)号：US20060127315A1

公开(公告)日：2006-06-15

申请号：US11198931

申请日：2005-08-05

申请人： Sudhir Shah

发明人： Sudhir Shah

IPC分类号： A61K49/00 ,  A61K31/195

CPC分类号： A61K31/195 ,  A61K31/16 ,  A61K31/4412 ,  A61K45/06 ,  A61K49/00 ,  A61K2300/00

摘要： A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure.

摘要翻译： 接受注射造影剂的人通过施用铁螯合剂来治疗。 铁螯合剂的施用可以基本上防止人类急性肾功能衰竭的发生。 铁螯合剂的施用可以降低急性肾功能衰竭的严重性和/或降低由于急性肾衰竭引起的肾脏疾病的严重程度。

公开(公告)号：US07587570B2

公开(公告)日：2009-09-08

申请号：US11421071

申请日：2006-05-31

申请人： Prasenjit Sarkar ,  Gauri Sudhir Shah

发明人： Prasenjit Sarkar ,  Gauri Sudhir Shah

IPC分类号： G06F12/08

CPC分类号： G06F3/0665 ,  G06F3/0605 ,  G06F3/067

摘要： A storage provisioning system generates a storage management framework comprising a resource model representing a set of storage devices for use by an application. The resource model comprises a set of data containers and at least one volume container such that the resource model provides storage to the application independent of a plurality of interfaces used by the set of storage devices. The volume container is a specialized data container that interfaces directly with the storage devices and represents a bottom of a storage stack comprising at least one data container and at least one volume container. The resource model comprises a rules module for governing the construction of the data containers and the volume container and association between the data containers and the volume container.

摘要翻译： 存储配置系统生成包括表示用于应用程序使用的一组存储设备的资源模型的存储管理框架。 资源模型包括一组数据容器和至少一个卷容器，使得该资源模型独立于该组存储设备使用的多个接口向应用提供存储。 卷容器是与存储设备直接接口的专用数据容器，并且代表包括至少一个数据容器和至少一个卷容器的存储堆栈的底部。 资源模型包括用于管理数据容器和卷容器的构造的规则模块以及数据容器和卷容器之间的关联。

公开(公告)号：US20050196869A1

公开(公告)日：2005-09-08

申请号：US11100129

申请日：2005-04-06

申请人： Sudhir Shah

发明人： Sudhir Shah

IPC分类号： A61K31/16 ,  A61K31/164 ,  A61K31/4412 ,  A61K31/4422 ,  G01N33/68 ,  G01N33/84 ,  G01N33/20

CPC分类号： G01N33/6893 ,  A61K31/16 ,  A61K31/164 ,  A61K31/195 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4422 ,  A61K31/444 ,  G01N33/84 ,  G01N2800/347

摘要： Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.

公开(公告)号：US20110112113A1

公开(公告)日：2011-05-12

申请号：US12882809

申请日：2010-09-15

申请人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

发明人： Mohan Rajapurkar ,  Suhas Lele ,  Sudhir Shah

IPC分类号： G01N33/50 ,  A61K31/4412 ,  A61K31/16 ,  A61K31/495 ,  A61K31/192 ,  A61P9/00

CPC分类号： G01N33/20 ,  A61K31/4439 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/56 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/811

摘要： The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

摘要翻译： 本发明提供了治疗急性冠状动脉综合征的方法，并且基于人类受试者的生物流体中催化铁的升高来预测不良心脏事件。 本发明的一个实施方案提供了在呈现胸痛时在人类受试者中早期检测急性冠状动脉综合征（ACS）的方法。 该方法包括分析生物流体的测试样品中的催化铁量并检测人类受试者的急性冠脉综合征。

公开(公告)号：US20070238760A1

公开(公告)日：2007-10-11

申请号：US11808595

申请日：2007-06-12

申请人： Sudhir Shah

发明人： Sudhir Shah

IPC分类号： A61K31/44

CPC分类号： G01N33/6893 ,  A61K31/16 ,  A61K31/164 ,  A61K31/195 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4422 ,  A61K31/444 ,  G01N33/84 ,  G01N2800/347

摘要： Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content, in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.

摘要翻译： 肾脏疾病是通过测量人体尿液催化铁来诊断的。 通过向人体施用铁螯合剂治疗进行性肾脏疾病。 特别地，肾病的进展基本上可以停止，并且通过向患有进行性肾脏疾病的人体施用铁螯合剂可以降低肾脏疾病的严重性。 所述方法包括测量患有进行性肾脏疾病的人的尿液中的催化铁含量，并向人体施用铁螯合剂。 该方法可以包括在给予铁螯合剂之前，期间或之后测量血样中的总尿蛋白含量，血尿素氮或肌酐。